1.
Strober B, Asahina A, Mrowietz U, Lebwohl M, Foley P, Langley R, Barker J, Cioffi C, Cross N, Wang M, Paul C. Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. J of Skin [Internet]. 2021Nov.5 [cited 2022Aug.11];5(6):s52. Available from: https://jofskin.org/index.php/skin/article/view/1403